Examining the Application of Immunoglobulin in Multiple Disease States: A Review of Evidence

https://www.pharmacytimes.org/on-demand/examining-the-application-of-immunoglobulin-in-multiple-disease-states-a-review-of-evidence

Related Videos

Related Content

Advertisement

July 4th 2025

5 Evidence-Based Practices to Help Older Adults Live Independently

Hayden E. Klein

Falls can often lead to reduced mobility or long-term disability in adults 65 and older, but there are strategies beyond exercise that can help these patients stay independent longer.

July 1st 2025

Why Collaborative Care Is the Path Forward for Mental Health Care: Anna Bob, MPH

Giuliana Grossi Anna Bob

Explore how the Collaborative Care Model enhances mental health access in this episode featuring Anna Bob, MPH, executive director of the Path Forward coalition.

July 3rd 2025

A Closer Look at Nipocalimab’s Impact on Myasthenia Gravis Care: Constantine Farmakidis, MD

Maggie L. Shaw Constantine Farmakidis, MD

Nipocalimab's FDA approval revolutionizes generalized myasthenia gravis treatment, offering rapid symptom relief and improved patient outcomes across diverse populations.

June 24th 2025

Addressing the Physical, Psychological Complexity of IBD Through Coordinated Care

Giuliana Grossi Skylar Jeremias Eva Szigethy, MD, PhD Benjamin Cohen, MD

Explore how the Specialty Medical Home model transforms care for patients with inflammatory bowel disease (IBD) by integrating mental health support and addressing stigma.

July 3rd 2025

Preference for Long-Acting vs On-Demand PrEP Seen in Black Men in the US

Julia Bonavitacola

Black men who were identified as sexual minorities were more receptive to long-acting injectable pre-exposure prophylaxis (PrEP) vs on-demand PrEP.

July 3rd 2025

Depemokimab Reduces Exacerbations Regardless of Baseline Asthma Control

Jared Kaltwasser

Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being reviewed by the FDA.

Related Content

Advertisement

July 4th 2025

5 Evidence-Based Practices to Help Older Adults Live Independently

Hayden E. Klein

Falls can often lead to reduced mobility or long-term disability in adults 65 and older, but there are strategies beyond exercise that can help these patients stay independent longer.

July 1st 2025

Why Collaborative Care Is the Path Forward for Mental Health Care: Anna Bob, MPH

Giuliana Grossi Anna Bob

Explore how the Collaborative Care Model enhances mental health access in this episode featuring Anna Bob, MPH, executive director of the Path Forward coalition.

July 3rd 2025

A Closer Look at Nipocalimab’s Impact on Myasthenia Gravis Care: Constantine Farmakidis, MD

Maggie L. Shaw Constantine Farmakidis, MD

Nipocalimab's FDA approval revolutionizes generalized myasthenia gravis treatment, offering rapid symptom relief and improved patient outcomes across diverse populations.

June 24th 2025

Addressing the Physical, Psychological Complexity of IBD Through Coordinated Care

Giuliana Grossi Skylar Jeremias Eva Szigethy, MD, PhD Benjamin Cohen, MD

Explore how the Specialty Medical Home model transforms care for patients with inflammatory bowel disease (IBD) by integrating mental health support and addressing stigma.

July 3rd 2025

Preference for Long-Acting vs On-Demand PrEP Seen in Black Men in the US

Julia Bonavitacola

Black men who were identified as sexual minorities were more receptive to long-acting injectable pre-exposure prophylaxis (PrEP) vs on-demand PrEP.

July 3rd 2025

Depemokimab Reduces Exacerbations Regardless of Baseline Asthma Control

Jared Kaltwasser

Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being reviewed by the FDA.